Studies on combination of platinum drugs cisplatin and oxaliplatin with phytochemicals anethole and curcumin in ovarian tumour models

Anticancer Research

Volumn 32, Issue 11, 2012, Pages 4843-4850

  Nessa, Meher U ^a   Beale, Philip ^b   Chan, Charles ^b   Yu, Jun Q ^a   Huq, Fazlul ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ANZAC Research Institute   (Australia)

Author keywords

Anethole; Cisplatin; Curcumin; Drug combination; Drug resistance; Oxaliplatin

Indexed keywords

ANETHOLE; CISPLATIN; CURCUMIN; OXALIPLATIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CELL ASSAY; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; OVARY CARCINOMA; PRIORITY JOURNAL;

ANISOLES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; CURCUMIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HUMANS; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PHYTOTHERAPY;

EID: 84872670307     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA: A Cancer J Clin 61(2): 69-90, 2011.
2. Boyle P and Levin B (eds.): World Cancer Report 2008. Lyon, France, International Agency for Research on Cancer (Part of World Health Organization), 2008.
3. Anon: Cancer Facts and Figures 2010. Atlanta, American Cancer Society, 2010. Available from: http://www.cancer.org/acs/groups/content/ @epidemiologysurveilance/documents/document/acspc-026238.pdf.
4. Gallion HH, Pieretti M, DePriest PD and van Nagell JR Jr.: The molecular basis of ovarian cancer. Cancer 76(10 Suppl): 1992-1997, 1995.
5. Marsden DE, Friedlander M and Hacker NF: Current management of epithelial ovarian carcinoma: A review. Semin Surg Oncol 19(1): 11-19, 2000.
6. Kim M-K, Kim K, Han JY, Lim JM and Song YS: Modulation of inflammatory signaling pathways by phytochemicals in ovarian cancer. Genes Nutrition 6(2): 109-115, 2011.
7. Ruhul AARM, Kucuk O, Khuri FR and Shin DM: Perspectives for cancer prevention with natural compounds. J Clin Oncol 27(16): 2712-2725, 2009.
8. Chen CH and deGraffenried LA: Anethole suppressed cell survival and induced apoptosis in human breast cancer cells independent of estrogen receptor status. Phytomedicine 19(8-9): 763-767, 2012.
9. Drukarch B, Schepens E, Stoof JC and Langeveld CH: Anethole dithiolethione prevents oxidative damage in glutathione-depleted astrocytes. Eur Pharmacol 329(2/3): 259-262, 1997.
10. Bouthillier L, Charbonneau M and Brodeur J: Assessment of the role of glutathione conjugation in the protection afforded by anethol dithiolthione against hexachloro-1,3-butadiene-induced nephrotoxicity. Toxicol Appl Pharmacol 139(1): 177-185, 1996.
11. Rajakumar DV and Rao MNA: Dehydrozingerone and isoeugenol as inhibitors of lipid peroxidation and as free radical scavengers. Biochem Pharmacol 46(11): 2067-2072, 1993.
12. Chainy GBN, Manna SK, Chaturvedi MM and Aggarwal BB: Anethole blocks both early and late cellular responses transduced by tumor necrosis factor: effect on NF-κB, AP-1, JNK, MAPKK and apoptosis. Oncogene 19(25): 2943-2950, 2000.
13. Aggarwal BB and Shishodia S: Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 71(10): 1397-1421, 2006.
14. Baeurle PA and Baichwal VR: NF-κB as a frequent target for immunosuppressive and anti-inflammatory molecules. Adv Immunol 65: 111-137, 1997.
15. Karin M: The regulation of AP-1 activity by mitogen-activated protein kinases. Phil Trans Royal Soci London, Biol Sci 351(1336): 127-134, 1996.
16. Eferl R and Wagner EF: AP-1: A double-edged sword in tumorigenesis. Nat Rev Cancer 3(11): 859-868, 2003.
17. HemaIswarya S and Doble M: Potential synergism of natural products in the treatment of cancer. Phytother Res 20(4): 239-249, 2006.
18. Sarkar FH, Li Y, Sarkar FH and Li Y: Using chemopreventive agents to enhance the efficacy of cancer therapy. Cancer Res 66(7): 3347-3350, 2006.
19. Kunnumakkara AB, Anand P and Aggarwal BB: Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett 269(2): 199-225, 2008.
20. Reuter S, Eifes S, Dicato M, Aggarwal BB and Diederich M: Modulation of anti-apoptotic and survival pathways by curcumin as a strategy to induce apoptosis in cancer cells. Biochem Pharmacol 76(11): 1340-1351, 2008.
21. Goel A, Kunnumakkara AB and Aggarwal BB: Curcumin as curecumin: From kitchen to clinic. Biochem Pharmacol 75(4): 787-809, 2008.
22. Hussain SP and Harris CC: Inflammation and cancer: An ancient link with novel potentials. Int J Cancer 121(11): 2373-2380, 2007.
23. Jobin C, Bradham CA, Russo MP, Juma B, Narula AS, Brenner DA and Sartor RB: Curcumin blocks cytokine-mediated NF-κB activation and proinflammatory gene expression by inhibiting inhibitory factor I-κB kinase activity. J Immunol 163(6): 3474-3483, 1999.
24. Plummer SM, Holloway KA, Manson MM, Munks RJ, Kaptein A, Farrow S and Howells L: Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex. Oncogene 18(44): 6013-6020, 1999.
25. Singh S and Aggarwal BB: Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]. J Biol Chem 270(42): 24995-25000, 1995.
26. Chan MM-Y, Huang H-I, Fenton MR and Fong D: In vivo inhibition of nitric oxide synthase gene expression by curcumin, a cancer preventive natural product with anti-inflammatory properties. Biochem Pharmacol 55(12): 1955-1962, 1998.
27. Zhang F, Altorki NK, Mestre JR, Subbaramaiah K and Dannenberg AJ: Curcumin inhibits cyclooxygenase-2 transcription in bile acid- and phorbol ester-treated human gastrointestinal epithelial cells. Carcinogenesis 20(3): 445-451, 1999.
28. Lin YG, Kunnumakkara AB, Nair A, Merritt WM, Han LY, Armaiz-Pena GN, Kamat AA, Spannuth WA, Gershenson DM, Lutgendorf SK, Aggarwal BB and Sood AK: Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappa B pathway. Clinical Cancer Res 13(11): 3423-3430, 2007.
29. Tan X, Sidell N, Mancini A, Huang R-P, Wang S, Horowitz IR, Liotta DC, Taylor RN and Wieser F: Multiple anticancer activities of EF24, a novel curcumin analog, on human ovarian carcinoma cells. Reprod Sci 17(10): 931-940, 2010.
30. Yunos NM, Beale P, Yu JQ, Strain D and Huq F: Studies on combinations of platinum with paclitaxel and colchicine in ovarian cancer cell lines. Anticancer Res 30(10): 4025-4038, 2010.
31. Yunos NM, Beale P, Yu JQ and Huq F: Synergism from sequenced combinations of curcumin and epigallocatechin-3-gallate with eisplatin in the killing of human ovarian cancer cells. Anticancer Res 31(4): 1131-1140, 2011.
32. Nessa MU, Beale P, Chan C, Yu JQ and Huq F: Synergism from combinations of cisplatin and oxaliplatin with quercetin and thymoquinone in human ovarian tumour models. Anticancer Res 31(11): 3789-3797, 2011.
33. Nessa MU, Beale P, Chan C, Yu JQ and Huq F: Combinations of resveratrol, cisplatin and oxaliplatin applied to human ovarian cancer cells. Anticancer Res 32(1): 53-60, 2012.
34. 2]. Indian J Chem 8: 193-194, 1970.
35. Alshehri A, Beale P, Yu JQ and Huq F: Synergism from combination of cisplatin and multicentred platinums coded as DH6Cl and TH1 in human ovarian tumour models. Med Chem 7(6): 593-598, 2011.
36. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65(1-2): 55-63, 1983.
37. Chou T-C: Relations between inhibition constants and fractional inhibition on enzyme-catalyzed reactions with different numbers of reactants, different reaction mechanisms, and different types and mechanisms of inhibition. Mol Pharmacol 10(2): 235-247, 1974.
38. Chou T-C: Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands. J Theor Biol 59(2): 253-276, 1976.
39. Barton C, Davies D, Balkwill F and Burke F: Involvement of both intrinsic and extrinsic pathways in IFN-γ-induced apoptosis that are enhanced with cisplatin. Eur J Cancer 41(10): 1474-1486, 2005.
40. Fulda S and Debatin KM: Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 25(34): 4798-4811, 2006.
41. Chen GG and Lai PBS (eds.): Apoptosis in Carcinogenesis and Chemotherapy: Apoptosis in Cancer. Springer Science, Hong Kong, 2009.
42. Banerjee S, Padhye S, Azmi A, Wang Z, Philip PA, Kucuk O, Sarkar FH and Mohammad RM: Review on molecular and therapeutic potential of thymoquinone in cancer. Nutr Cancer 62(7): 938-46, 2010.
43. Solomon LA, Ali S, Banerjee S, Munkarah AR, Morris RT and Sarkar FH: Sensitization of ovarian cancer cells to cisplatin by genistein: The role of NF-kappaB. J Ovarian Res 1(1): 9, 2008.